Nagourney Cancer Institute

Nagourney Cancer Institute was founded in 1995 by Dr. Robert Nagourney. The institute has developed the Ex Vivo Analysis of Programmed Cell Death (EVA-PCD) assay, a state-of-the-art functional profiling test that produces a functional/phenotypic profile of a patient’s cancer. This analysis, based on tumor biology, identifies in real-time which therapies induce the cancer cells to shut down and die, helping patients and their doctors choose the most effective, least toxic treatment. The EVA-PCD analysis has shown to double response rates and increase survival. The institute also provides services to pharmaceutical companies by determining the efficacy of new drugs in a variety of human tumor diagnoses. Nagourney Cancer Institute accepts samples from around the world and provides timely results for most types of cancers. Dr. Nagourney, who is available for clinical consultations, owns and operates the institute. He is a frequently invited speaker, an active blogger, and the author of the book Outliving Cancer. The institute has been featured on national and local television and in major newspapers. For specific cases, patients can contact the Patient Relations Representatives at 1-800-542-4357. Nagourney Cancer Institute stands as the only cancer testing laboratory with an onsite practicing hematologist/oncologist. The institute operates within the Biotechnology, Health Care, and Pharmaceutical industries.